PhotoBiotics Announces Collaboration with Major Pharma Company
London, 7th December 2010
PhotoBiotics Ltd announced today that it has entered into a funded collaboration and option agreement with a top-5 pharma company.
This will explore the benefits of PhotoBiotics’ unique proprietary OptiLink antibody-drug conjugation (ADC) platform in a new indication. Further details were not disclosed.
"This is an important endorsement for PhotoBiotics," Dr Till Medinger, PhotoBiotics’ chairman added, "We are delighted to be working with a pharma giant and look forward to seeing the benefits of our unique ADC technology for targeted imaging and therapy being applied in additional indications".
About PhotoBiotics
PhotoBiotics, a spin-out company from Imperial College London, has developed and patented OptiLink, a unique yet simple conjugation platform that optimises the multiple attachment of drugs to antibody fragments. This allows drugs to be precisely targeted, enhancing efficacy and selectivity, with the prospect of developing breakthrough products for therapy and diagnostic imaging across multiple indications, and tackling substantial unmet medical needs. These products are known as antibody-drug conjugates (ADCs) and are particularly relevant in today’s market, especially as the era of personalised medicines is becoming a reality. The application of PhotoBiotics’ technology is leading to better, safer drugs.
For more information please contact:
Dr Lionel R Milgrom, PhotoBiotics Ltd Press Office,
Tel: +44 (0)208 450 8760
Mob: +44 (0)7970 852156
Email:
Press Releases
- PhotoBiotics' CSO presents at World ADC Summit in Frankfurt
Date : 01 March 2012 - PhotoBiotics' COO presents at major Antibody Drug Conjugate (ADC) conference in Barcelona
Date : 09 November 2011 - PhotoBiotics presents OptiLinkTM Antibody-drug conjugate (ADC) platform at World ADC Summit in San Francisco
Date : 25 October 2011 - PhotoBiotics Raises Further Funding for Antibody Drug Conjugates (ADCs)
Date : 11 October 2011 - PhotoBiotics' CSO hosts Antibody Drug Conjugate (ADC) event at Berlin Novel Protein Therapeutics Conference
Date : 27 September 2011 - A Conjugation Platform for the Targeted Delivery of Anticancer Agents
Date : 01 September 2011 - OptiLink ADC Technology Features at the 10th Annual Congress on Recombinant Antibodies
Date : 15 May 2011 - PhotoBiotics Announces Collaboration with Major Pharma Company
Date : 7 December 2010 - PhotoBiotics’ approach to Targeted Magnetic Resonance Imaging receives award from the National Institute for Health Research
Date : 6 September 2010 - Location! Location! Location! - PhotoBiotics' Key to Successful PDT
Date : 31 July 2010 - US patent granted to PhotoBiotics for new targeted cancer therapy
Date : 1 April 2010 - Targeted Photodynamic Therapy in Corfu and Wroclaw 2009
Date : 22 June 2009 - American Chemical Society Hosts Targeted Photodynamic Therapy at Salt Lake City
Date : 10 April 2009 - Patent for targeted photodynamic therapy (t-PDT) gets green light Down Under
Date : 7 October 2008 - Targeted Photodynamic Therapy (t-PDT) to light up Brixen / Bressanone Symposium
Date : 18 September 2008 - Novel Targeted Cancer Therapy on show at Dubrovnik
Date : 24 March 2008 - New targeted anti-cancer therapy lights up investors
Date : 29 January 2008 - Light-activated anti-cancer drugs on target
Date : 29 November 2007